Colton Jones, MD, on GLP-1 RAs for the Prevention of HCC in High-Risk Individuals
ASCO 2026
Colton Jones, MD, of The University of Texas at San Antonio, talks about the results of a global, multicenter analysis that sought to determine the safety and efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the primary prevention of hepatocellular carcinoma (HCC) in a pan-etiology high-risk cohort (Abstract 10522).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Hepatocellular carcinoma is a major cause of cancer related morbidity and mortality. Currently, there are no FDA approved medications for risk reduction or primary prevention of hepatocellular carcinoma. There has been a lot of evidence regarding reduction in hepatocellular carcinoma with GLP-1 agonist, particularly in patients with type 2 diabetes and in patients with metabolic associated steatotic liver disease. However, to date, there is no study that's been conducted for risk reduction of hepatocellular carcinoma in patients who have other etiologies such as alcohol, liver cirrhosis and viral hepatitis along with hereditary liver disease. This is where our study comes into play and it fills a significant gap in the medical literature. We used the TriNetX database, which is a large commercial database encompassing over 150 million participants across 112 healthcare organizations. We identified participants who were on a GLP-1 medication for more than two months and we compared it to those who are not on a GLP-1, specifically focusing on high risk participants. And we defined high risk as those participants with a history of liver cirrhosis, chronic viral hepatitis or any other hereditary related liver disease in addition to those with obesity and type 2 diabetes. At a median follow up of 2400 plus days for GLP users and 2114 days for non users, what our study found was there was an association of a 73% risk reduction in incident hepatocellular carcinoma. This risk reduction was even greater in nondiabetics and in those with a lean BMI. This was associated with an almost 80% risk reduction. In addition, there was a risk reduction in the other related groups including alcoholic cirrhosis, viral hepatitis and in those with hereditary liver conditions. We assess safety outcomes in the study and particularly we looked at gastrointestinal adverse events. GLP users were associated with a higher risk of nausea and vomiting as well as diarrhea and a lower incidence of pancreatitis and acute kidney injury. Gastrointestinal adverse events are known side effects of GLP-1 users. So in summary, our study found that there was almost a 73% risk reduction in incident hepatocellular carcinoma for GLP users and this was significant throughout all subgroups. These findings, though hypothesis-generating, require prospective validation as they may implicate a public health impact.
Related Videos
The ASCO Post Staff
Atish Choudhury, MD, PhD, of Dana-Farber Cancer Institute, talks about findings from the phase II A-DREAM/Alliance A032101 trial, which explored the possibility of androgen-deprivation (ADT) interruption in patients with metastatic hormone-sensitive prostate cancer who had an exceptional response to androgen receptor pathway inhibitors (ARPIs) (Abstract 5004).
The ASCO Post Staff
François-Clément Bidard, MD, PhD, of Institut Curie, presents final progression-free survival 2 findings from the phase III SERENA-6 trial, which investigated the efficacy of camizestrant, a selective estrogen receptor degrader (SERD), vs continued aromatase inhibition in patients with advanced breast cancer with emergent ESR1 mutations. Earlier reports from the trial showed improved progression-free survival with the SERD (Abstract LBA1007).
The ASCO Post Staff
Mali Barbi, MD, MS, of Northwell Health Cancer Institute Center for Women's Cancer, discusses durable survival benefits shown in the NRG-GY018 trial with pembrolizumab and the RUBY trial with dostarlimab for patients with mismatch repair–deficient (dMMR) endometrial cancer. In addition, B7-H4 antibody-drug conjugates such as puxitatug samrotecan are emerging as options for relapsed/metastatic disease.
The ASCO Post Staff
Katharina C. Kaehler, MD, of University Hospital (UKSH), Campus Kiel, presents an update on the primary outcome and sensitivity analyses from the PIVOTAL phase III trial of daromun, a combination of two fibronectin-targeting immunocytokines (L19IL2 and L19TNF), as a neoadjuvant intralesional therapy in patients with resectable, locally advanced stage III melanoma (Abstract LBA9517).
The ASCO Post Staff
Julie R. Brahmer, MD, FASCO, of the Bloomberg–Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, provides expert commentary on the overall survival results from the phase III HARMONi-6 trial presented in this year’s Plenary Session. The study compared ivonescimab plus chemotherapy vs tislelizumab plus chemotherapy in previously untreated patients with advanced squamous non–small cell lung cancer (NSCLC) (Abstract LBA4).